NASDAQ · ANTXHealthcarePharmaceuticals

AN2 Therapeutics news

$5.09+1.60%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days1English, de-duplicated

Positive1100% of coverage

Neutral00%

Negative00% of coverage

About AN2 Therapeutics

No recent articles focused on AN2 Therapeutics.

Also mentions ANTX

Articles that tag ANTX but are mainly about other companies.

Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

GlobeNewswire Inc.Aug 31, 1:00 PM ET▲ Positive

Developing Epetraborole as an emerging NTM therapy with potential to address unmet treatment needs in the expanding market.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology